Replimune Group Inc (REPL NASDAQ) stock market data APIs
$12.7689
-0.93(-7.3%)
as of August 6, 2026
Try our APIs with
free plan!
Replimune Group Inc Financial Data Overview
Price chart is built with
Anychart
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Prev. Close
12.7689
Open
11.8359
High
13.8485
Low
11.6075
52 wk Range
1.5-13.9
Market Cap
1 081 M
Shares Outstanding
84 026 K
EPS
-0.95
Beta
0.9
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Replimune Group Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Replimune Group Inc data using free add-ons & libraries
Get Replimune Group Inc Fundamental Data
Replimune Group Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -312 555 008
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-06
- EPS/Forecast: -0.71
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Replimune Group Inc News
New
Replimune Wins FDA Accelerated Nod For TUDRIQEVTM In Advanced Melanoma
(RTTNews) - Replimune Group, Inc. (REPL) announced that the U.S. FDA has granted accelerated approval for TUDRIQEVTM, in combination with Nivolumab (Bristol Myers Squibb), for adults with unresectable...
Replimune gains accelerated approval of Tudriqev for cutaneous melanoma
[Dermoscopic image of malignant melanoma skin tumor] Izzet Esmece/iStock via Getty Images * The US FDA has granted accelerated approval to Replimune's (REPL [https://seekingalpha.com/symbol/REPL]) ...
Bragar Eagel & Squire, P.C. is Investigating Replimune Group Inc. on Behalf of Replimune Stockholders and Encourages Investors to Contact the Firm
If you purchased or acquired stock in Replimune and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@besp...
Biotech Stocks At 52-Week Highs - UFPT +25%, INFU +33%, SOPH +20% On Q2 Reports, REPL, PBLS
(RTTNews) - The following biotech stocks reached a 52-week high on August 4, 2026, driven by key catalysts like positive quarterly results or certain regulatory milestones. UFP Technologies Inc. (UFP...
Get Replimune Group Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
